Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

Open
75N98027R00020Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

325411 - Medicinal and Botanical Manufacturing

Place of Performance

6138, MD, USA

Set-Aside

NONE

Documents

1
DOCX

Read the document

Due in 14 days

Every page of every file, in your free workspace.

Read the document

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Due in 14 days

Everything you need to bid on this one

Open the full contract in your free workspace.

  • 1 solicitation documentRead every page
  • Buyer contactEmail and phone
Open the full contract

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseSources Sought
Posted

Sources Sought

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida
Contacts1 person available
OfficeBethesda, MD, 20892, USA

Full Description

Show more

Title:  Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics 


This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.


This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition.  It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract.  Responses will not be considered as proposals or quotes.  No award will be made as a result of this notice.  The Government will NOT be responsible for any costs incurred by the respondents to this notice.  This notice is strictly for research and information purposes only.


The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible.


Background:  The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. 


Please see the attachment for more details.

Similar Contracts

Same NAICS industry code

NAICS: 325411
New
DIBBS
ANALGESIC GEL, TOPICAL
Solicitation # SPE2DP-27-T-0371
Solicitation SPE2DP-27-T-0371 is a Request for Quotations issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Biofreeze topical analgesic gel. The requirement consists of four units of colorless gel containing 5% Menthol USP in 4 oz (118ml) tubes, intended for use by adults and children aged two years and older. The product is classified as a Type I (Code M) item with a non-extendable shelf life of 24 months and must be stored in a cool, dry place between 20-25 C (68-77 F) away from direct sunlight. Due to its flammable nature, the gel must be kept away from excessive heat or open flames. Delivery is specified as FOB Destination to the 0024 QM Co Composite Suppl at Joint Base Lewis MCCH, WA, with a required delivery date of November 16, 2026, and a delivery window of 20 days. Packaging must follow MIL-STD-2073-1E and RP001 DLA packaging requirements, utilizing suitable sealed unit containers and commercial exterior shipping containers. Marking must strictly adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129. The contract incorporates various FAR and DFARS clauses, including requirements for equal opportunity for workers with disabilities, safeguarding covered defense information, and compliance with the Buy American Act and Berry Amendment. Invoicing and payment must be processed electronically through the Wide Area WorkFlow (WAWF) system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 7 days
View Details
NAICS: 325411
New
DIBBS
KETOROLAC TROMETHAMINE
Solicitation # SPE2DP-27-T-0291
This procurement, solicitation SPE2DP-27-T-0291, is a small business set-aside issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the acquisition of Ketorolac Tromethamine Injection. The requirement is for 10 packages of USP 15 mg per ml solution provided in pre-filled syringes, identified by NSN 6505-01-666-2156. The product is classified as a Type I (Code M) item with a non-extendable shelf life of 24 months. Delivery is required FOB Destination to the 1AD Sustainment Brigade SSA at Fort Bliss, Texas, with a required delivery date of November 13, 2026, and a delivery timeline of 20 days. The contract mandates strict adherence to Medical Marking Standard No. 1, which supersedes MIL-STD-129 for medical marking, although MIL-STD-129 remains applicable for general shipment and storage. Packaging must be commercial and include suitable sealed unit containers, with specific requirements for hazardous materials under FED-STD-313 and TQ requirement IP025. Suppliers must submit Safety Data Sheets and Hazard Communication Standard labels for review prior to award. Inspection and acceptance will occur at the destination. Administrative requirements include the use of the Wide Area WorkFlow system for invoicing and compliance with various FAR and DFARS clauses regarding cybersecurity, domestic preferences, and small business representations.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

4 days ago

DEADLINE

in 2 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Nida

Same awarding agency

NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006OT
The National Institute on Drug Abuse (NIDA) is issuing a Sources Sought Notice to identify qualified business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is not a solicitation for proposals, but a market research effort to determine the availability of technically capable commercial or non-commercial sources and to identify the appropriate acquisition method. The scope of work involves producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, ensuring purity levels of at least 95 percent, and managing the secure storage and shipment of these compounds to research investigators. Interested vendors must demonstrate the ability to handle large quantities of DEA controlled and uncontrolled substances, including peptides, narcotics, and stimulants, some of which require refrigeration. A mandatory requirement for any capable vendor is the possession of a DEA Research Registration for Schedules II through V and the ability to obtain registration for Schedule I substances. Organizations must submit a capability statement of no more than ten pages, including their UEI number, business size, and detailed evidence of staff expertise and prior experience, to the designated Contract Specialist by November 20, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541715
Federal
Synthesis and Distribution of Drugs of Abuse and Related Compounds
Solicitation # 75N98027R00006SB
The National Institute on Drug Abuse (NIDA) is issuing a Small Business Sources Sought Notice to identify qualified small business organizations capable of supporting the synthesis and distribution of drugs of abuse and related compounds. This is a market research effort to determine the availability of technically capable sources and to decide if a small business set-aside is appropriate under NAICS code 541715. The scope of work includes producing, acquiring, and maintaining an inventory of labeled and unlabeled chemical substances, testing for purity, managing the Drug Inventory Supply Control System (DISCS), and ensuring the secure storage and shipment of compounds to research investigators. Interested vendors must demonstrate the ability to store large quantities of DEA-controlled and uncontrolled substances, including peptides, while maintaining a purity level of at least 95 percent. A mandatory requirement for this effort is that vendors possess a DEA Research Registration for Schedules II through V and show the capability to obtain registration for Schedule I substances. Qualified small businesses must submit a capability statement, limited to ten pages, to the designated contract specialist by November 20, 2026. This notice is for information purposes only and does not constitute a solicitation or a commitment to award a contract.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

18 days ago

DEADLINE

in 4 days
View Details
NAICS: 541690
Federal
Modification to Extend Services for Scientific, Operations and Administrative Resources (SOAR) Contract Program
Solicitation # OLAO-SSD-SOAR-NOI
The National Institutes of Health (NIH) intends to negotiate and award non-competitive modifications to extend the Scientific, Operations and Administrative Resources (SOAR) contract program. This program consists of five indefinite-delivery, indefinite-quantity (IDIQ) contracts held by Axle Informatics LLC, Gap Solutions Inc., Kelly Services Inc., Guidehouse Digital LLC, and 22nd Century Technologies Inc. The primary objective is to ensure continuity of specialized scientific professional services across 29 NIH organizations, including the Office of the Director, 27 Institutes and Centers, and ARPA-H, while the agency finalizes a strategic procurement consolidation effort and a competitive follow-on acquisition. The proposed extension includes a basic ordering period from June 22, 2026, to June 21, 2027, with two optional six-month extensions extending through June 21, 2028. Additionally, the government seeks to revise FAR 52.216-22 to allow task orders to extend up to 36 months beyond the parent contract end date. While the combined maximum contract ordering value remains unchanged at $3,600,713,546, the estimated total dollar value for orders through the end of the extension is $2,174,615,674. The government projects the award of these modifications in April 2026. The SOAR program provides critical scientific staffing, such as bioinformatics scientists and molecular biologists, to support biomedical research and public health missions. The NIH has cited a critical need for these specific contract holders to avoid disruptions to ongoing research and patient diagnostics. Interested parties may submit capability statements and pricing information by March 5, 2027, although the government currently intends to proceed on a non-competitive basis with the existing holders.
Other Scientific and Technical Consulting Services

POSTED

9 months ago

DEADLINE

in 4 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS